A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- Acronyms ERIBRAIN
- 25 Sep 2019 Planned End Date changed from 28 Mar 2023 to 28 Mar 2024.
- 25 Sep 2019 Planned primary completion date changed from 16 Mar 2023 to 16 Mar 2024.
- 25 Sep 2019 Status changed from not yet recruiting to recruiting.